Results 221 to 230 of about 2,720,692 (363)
APOBEC3A is the predominant global editor of cytosines in human mRNAs and in single-strand RNA viruses. [PDF]
G3 (Bethesda)Kockler ZW +11 more
europepmc +1 more source
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
Molecular Oncology, EarlyView.Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller +10 more
wiley +1 more source
Improving iSpyMacCas9 multiplex genome editing in rice by CRISPR-combo-mediated BBM1 activation. [PDF]
Plant JByiringiro I +5 more
europepmc +1 more source
A concept for the editing of hardware resulting in an automatic hardware-editor
, 1977 Franz J. Rammig
openalex +2 more sources
The evolving landscape of gene editing therapies for human genetic diseases: a twenty-year bibliometric analysis. [PDF]
Front Med (Lausanne)Zhou X +5 more
europepmc +1 more source
Molecular Oncology, EarlyView.Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source